BioSpace News Archive

Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company principally focused on the development of innovative regenerative medicine and biological therapeutics, has closed its previously announced $4.0 million capital raise at $0.02 and corporate restructuring transaction.

Adastra Holdings Ltd. (CSE:XTRX)(FRA:D2EP) (“Adastra” or the “Company”), a leading cannabis company focused on processing, adult-use and medical sales, organoleptic testing and analytical testing, is pleased to report financial results for the three and six months ended June 30, 2022.

ProSomnus Sleep Technologies (“ProSomnus”), the leader in patient-preferred medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced the execution of definitive agreements with institutional investors led by funds affiliated with or managed by Cohanzick Management, LLC and CrossingBridge Advisors, LLC

This week, the Association of Clinical Research Organizations (ACRO)’s Diversity and Inclusion in Clinical Trials committee is proud to share ACRO’s Diversity, Equity, and Inclusion Principles Statement.

Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the third quarter of 2022.

89bio, Inc. announced the presentation of data from ENTRIGUE, its Phase 2 proof-of-concept trial of pegozafermin in severe hypertriglyceridemia at the European Society of Cardiology Congress 2022.

iZafe Group AB presents, August 26, its report for the second quarter.

Royal Philips, a global leader in health technology, will showcase its latest integrated cardiology solutions at the European Society of Cardiology Congress.

The diagnostic company SphingoTec GmbH announces the introduction of novel biomarker penKid in the clinical routine management of patients on a test basis in a total of four units at the University Hospital Heidelberg and Heidelberg Kidney Center.

Sema4 today announced that the Company has appointed Kevin Feeley as Chief Financial Officer (CFO), completing its previously announced search for the CFO position.